Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2015

01-01-2015 | Original Paper

Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?

Authors: Wenxi Yu, Lina Tang, Feng Lin, Yang Yao, Zan Shen

Published in: Medical Oncology | Issue 1/2015

Login to get access

Abstract

Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. But its role in neoadjuvant/adjuvant chemotherapy of osteosarcoma is still not defined. We conducted a retrospective evaluation of THP-containing chemotherapy for osteosarcoma in comparison with ADM-containing chemotherapy to determine differences in efficacy and toxicities between THP- and ADM-containing regimens. From January 2008 to May 2011, 112 stage IIB limb high-grade osteosarcoma patients were treated in our institute. Fifty-four patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of THP (pirarubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate), while 58 patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of ADM (doxorubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate). Efficacy and toxicity of the 2 anthracyclines given as combination chemotherapy were assessed in these patients. The limb salvage rate, histologic response rate, 2-year recurrence rate, 2-year metastasis rate, 2-year disease-free survival rate, 2-year overall survival rate, median disease-free survival time (DFS) and median overall survival time (OS) in THP-containing group were similar to that in ADM-containing group. Toxicities were well balanced in two groups. No death related to chemotherapy was observed. Left ventricular ejection fraction was unchanged 1 and 2 years after chemotherapy in two groups. Efficacy and toxicity of THP-containing combination are similar to those of ADM-containing combination in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma.
Literature
1.
Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341(5):342–52.PubMedCrossRef
2.
Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(8):893–9.PubMedCrossRef
3.
Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18(24):4016–27.PubMed
4.
Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP. Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574–80.PubMedCrossRef
5.
Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, Stenwig AE, Willén H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O, Saeter G. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39(4):488–94.PubMedCrossRef
6.
Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):137–9.PubMed
7.
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.CrossRef
8.
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo). 1979;32(10):1082–4.CrossRef
9.
Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, Mizoguchi H, Shibata A, Saito H, Matsuda T, Masaoka T, Harada M, Niho Y, Takaku F. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol. 2005;81(3):246–54.PubMedCrossRef
10.
Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H. Apoptosis in young rats with adriamycin-induced cardiomyopathy–comparison with pirarubicin, a new anthracycline derivative. Pediatr Res. 2002;51(2):256–9.PubMedCrossRef
11.
Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue—are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992;28A(10):1670–6.PubMedCrossRef
12.
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo). 1979;32(10):1085–6.CrossRef
13.
Pouna P, Bonoron AS, Gouverneur G, Tariosse L, Besse P, Robert J. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol. 1995;35:257–61.PubMedCrossRef
14.
Hirano S, Wakazono K, Agata N, Iguchi H, Tone H. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res. 1994;20:153–60.PubMed
15.
Okada Y, Horikawa K, Sano M. Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy. Gan To Kagaku Ryoho. 1997;24:585–9.PubMed
16.
Liu SY, Song SX, Lin L, Liu X. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy. 2010;56(2):101–7.PubMedCrossRef
17.
Zheng SE, Xiong S, Lin F, Qiao GL, Feng T, Shen Z, Min DL, Zhang CL, Yao Y. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin. 2012;33(6):832–8.PubMedCentralPubMedCrossRef
18.
He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, Yang Y, Yao Y. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. Int J Clin Oncol. 2013;18(3):498–505.PubMedCrossRef
19.
Qi WX, He AN, Tang LN, Shen Z, Yao Y. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol. 2012;29(3):2229–33.PubMedCrossRef
20.
Zhao H, Yao Y, Wang Z, Lin F, Sun Y, Chen P. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother. 2010;22(2):119–24.PubMedCrossRef
21.
Futani H, Fukunaga S, Tsukamoto Y, Terada N, Ono J, Okamoto N, Otsuka Y, Tanizawa T, Tomatsuri M, Yoshiya S. Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin. Anticancer Res. 2012;32(3):965–71.PubMed
22.
Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother. 2002;36(6):996–9.PubMedCrossRef
23.
Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun Y, Shen Z, Yao Y, Dong Y. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7(3):270–5.PubMedCrossRef
24.
Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, Bertoni F, Guerra A, Capanna R, Albisinni U. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer. 1985;56(7):1515–21.PubMedCrossRef
25.
26.
Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, Dominkus M, Saeter G. Osteosarcoma over the age of forty. Eur J Cancer. 2003;39(2):157–63.PubMedCrossRef
27.
Campanacci M, Enneking WF. High grade osteosarcomas. In: Bone and soft tissue tumors. Second, completely revised edition by Piccin Nuova Libraria S.p.A, Padova, Italy. New York: Springer; 1999. p. 464–8.
28.
Damron TA, Ward WG, Steward MA. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. National cancer data base report. Clin Orthop Relat Res. 2007;459:40–7.PubMedCrossRef
29.
Bacci G, Ferrari S, Donati D, Longhi A, Bertoni F, Di Fiore M, Comandone A, Cesari M, Campanacci M. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep. 1998;5(5):1259–63.PubMed
Metadata
Title
Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?
Authors
Wenxi Yu
Lina Tang
Feng Lin
Yang Yao
Zan Shen
Publication date
01-01-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0307-y

Other articles of this Issue 1/2015

Medical Oncology 1/2015 Go to the issue

Original Paper

Topotecan combined with Ifosfamide, Etoposide, and l-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma

Original Paper

Sonic hedgehog–Gli1 signals promote epithelial–mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway

Original Paper

MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability

Original Paper

Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer

Original Paper

Correlation and malignant transformation of MSCs with the overexpression of SIL-R/GP130 under the tumor microenvironment

Original Paper

CNS metastases in breast cancer patients: prognostic implications of tumor subtype
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits